Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | GMNN | O75496 | 1/20 | 0.42 |
| ▸ | PPM1B | O75688 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.42 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | PPP5C | P53041 | 1/20 | 0.42 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | FNTA | P49354 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL598374 | 1.00 | KDM4E (0.42) | KDM4EGMNNPPM1BLMNAPPP1CC | |
| SCHEMBL45910 | 1.00 | KDM4E (0.42) | KDM4EGMNNPPM1BLMNAPPP1CC | |
| SCHEMBL15324 | 1.00 | KDM4E (0.42) | KDM4EGMNNPPM1BLMNAPPP1CC | |
| SCHEMBL38660910 | 1.00 | KDM4E (0.42) | KDM4EGMNNPPM1BLMNAPPP1CC | |
| SCHEMBL45891 | 1.00 | KDM4E (0.42) | KDM4EGMNNPPM1BLMNAPPP1CC | |
| SCHEMBL34170 | 1.00 | KDM4E (0.42) | KDM4EGMNNPPM1BLMNAPPP1CC | |
| SCHEMBL24453322 | 0.97 | KDM4E (0.40) | KDM4EGMNNPPM1BLMNAPPP1CC | |
| SCHEMBL20963086 | 0.97 | KDM4E (0.40) | KDM4EGMNNPPM1BLMNAPPP1CC | |
| SCHEMBL20963058 | 0.97 | KDM4E (0.40) | KDM4EGMNNPPM1BLMNAPPP1CC | |
| SCHEMBL16020384 | 0.97 | STS (0.40) | KDM4EGMNNPPM1BLMNAPPP1CC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116514804-A | Cathepsin K inhibitor, preparation method and application thereof | 山东新时代药业有限公司 | 2023-08-01 | — | — | CN | claimed |
| CN-116377727-A | Laser stealth coating for fabric and application method thereof | 西京学院 | 2023-07-04 | — | — | CN | claimed |
| CN-116514804-A | Cathepsin K inhibitor, preparation method and application thereof | 山东新时代药业有限公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-116377727-A | Laser stealth coating for fabric and application method thereof | 西京学院 | 2023-07-04 | — | — | CN | disclosed |
| WO-2023118253-A1 | CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-06-29 | — | — | WO | disclosed |
| CN-110300792-B | Liquid crystal aligning agent composition, method for preparing liquid crystal alignment film using the same, and liquid crystal alignment film using the same | 株式会社LG化学 | 2022-12-20 | — | — | CN | disclosed |
| US-20200046725-A1 | Prodrug Comprising a Drug Linker Conjugate | ASCENDIS PHARMA A/S (DK) | 2020-02-13 | — | — | US | disclosed |
| US-20190040191-A1 | RECYCLABLE POLYMERS BASED ON RING-FUSED GAMMA-BUTYROLACTONES | NATIONAL SCIENCE FOUNDATION | 2019-02-07 | — | — | US | disclosed |
| EP-2166412-B1 | Method of producing a polymerized carbon nanotube composite using a composition comprising carboxylated carbon nanotubes surface-modified with polymerizable moieties | SAMSUNG ELECTRONICS CO LTD (KR) | 2019-01-16 | — | — | EP | disclosed |
| US-20170253614-A1 | HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS | CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD. (CN) | 2017-09-07 | — | — | US | disclosed |
| US-20170100490-A1 | Prodrug Comprising a Drug Linker Conjugate | ASCENDIS PHARMA A/S (DK) | 2017-04-13 | — | — | US | disclosed |
| WO-2014025759-A1 | IAP ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-02-13 | — | — | WO | disclosed |
| US-20130012697-A1 | METHOD OF PRODUCING A METAL PHTHALOCYANINE COMPOUND, AND METHOD OF PRODUCING A PHTHALOCYANINE COMPOUND AND AN ANALOGUE THEREOF | FUJIFILM CORPORATION (JP) | 2013-01-10 | — | — | US | disclosed |
| US-8299240-B2 | Method of producing a metal phthalocyanine compound, and method of producing a phthalocyanine compound and an analogue thereof | FUJIFILM CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8110265-B2 | Pet container and compositions having enhanced mechanical properties and gas barrier properties | THE COCA-COLA COMPANY (US) | 2012-02-07 | — | — | US | disclosed |
| US-20100143546-A1 | CONTAINER AND COMPOSITION FOR ENHANCED GAS BARRIER PROPERTIES | THE COCA-COLA COMPANY (US) | 2010-06-10 | — | — | US | disclosed |
| WO-2010008117-A1 | CINCHONA-BASED BIFUCNTIONAL ORGANOCATALYSTS AND METHOD FOR PREPARING CHIRAL HEMIESTERS USING THE SAME | SUNGKYUNKWAN UNIVERSITY FOUNDATION FOR CORPORATE COLLABORATION (KR) | 2010-01-21 | — | — | WO | disclosed |
| US-20090247742-A1 | METHOD OF PRODUCING A METAL PHTHALOCYANINE COMPOUND, AND METHOD OF PRODUCING A PHTHALOCYANINE COMPOUND AND AN ANALOGUE THEREOF | FUJIFILM CORPORATION (JP) | 2009-10-01 | — | — | US | disclosed |
| WO-2007080066-A2 | 2,4,6-TRIALKYLPHENYL SUBSTITUTED CYCLOPENTANE-1,3-DIONE | BAYER CROPSCIENCE AG (DE) | 2007-07-19 | — | — | WO | disclosed |
| WO-2005019325-A1 | LOW DENSITY POLYETHYLENE ARTICLES EXHIBITING SIGNIFICANTLY DECREASED WARPAGE AT REDUCED COOLING TIMES | MILLIKEN & COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253614-A1 | HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS | HAVCR2, HCCS, LIPC | KDM4E 3963/4885GMNN 3067/4885PPM1B 364/4885 |
| US-20170100490-A1 | Prodrug Comprising a Drug Linker Conjugate | H1-0, H1-3, H1-2 | KDM4E 1446/4885GMNN 4370/4885PPM1B 4413/4885 |
| US-20200046725-A1 | Prodrug Comprising a Drug Linker Conjugate | H1-0, H1-3, H1-2 | KDM4E 1424/4885GMNN 4370/4885PPM1B 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.